[HTML][HTML] Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
[HTML][HTML] The hallmarks of cancer metabolism: Still emerging
Metabolism of cancer cells is geared toward biomass production and proliferation. Since the
metabolic resources within the local tissue are finite, this can lead to nutrient depletion and …
metabolic resources within the local tissue are finite, this can lead to nutrient depletion and …
[HTML][HTML] Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance
MH Sherman, GL Beatty - Annual Review of Pathology …, 2023 - annualreviews.org
Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …
[HTML][HTML] Cancer neuroscience: State of the field, emerging directions
The nervous system governs both ontogeny and oncology. Regulating organogenesis
during development, maintaining homeostasis, and promoting plasticity throughout life, the …
during development, maintaining homeostasis, and promoting plasticity throughout life, the …
Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
Emerging therapies in cancer metabolism
Y Xiao, TJ Yu, Y Xu, R Ding, YP Wang, YZ Jiang… - Cell Metabolism, 2023 - cell.com
Metabolic reprogramming in cancer is not only a biological hallmark but also reveals
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …
treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment …
[HTML][HTML] Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
J Encarnación-Rosado, ASW Sohn, DE Biancur, EY Lin… - Nature cancer, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …
[HTML][HTML] Amino acid depletion therapies: starving cancer cells to death
M Butler, LT van der Meer, FN van Leeuwen - Trends in Endocrinology & …, 2021 - cell.com
Targeting tumor cell metabolism is an attractive form of therapy, as it may enhance treatment
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …
response in therapy resistant cancers as well as mitigate treatment-related toxicities by …
Epithelial and stromal co-evolution and complicity in pancreatic cancer
SR Hingorani - Nature Reviews Cancer, 2023 - nature.com
Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …